- Home
- MYPS vs GNLX Comparison
MYPS vs GNLX Comparison
Compare MYPS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYPS
- GNLX
- Stock Information
- Founded
- MYPS 2011
- GNLX 2001
- Country
- MYPS United States
- GNLX United States
- Employees
- MYPS N/A
- GNLX N/A
- Industry
- MYPS EDP Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- MYPS Technology
- GNLX Health Care
- Exchange
- MYPS Nasdaq
- GNLX Nasdaq
- Market Cap
- MYPS 118.5M
- GNLX 128.0M
- IPO Year
- MYPS N/A
- GNLX 2023
- Fundamental
- Price
- MYPS $0.96
- GNLX $5.59
- Analyst Decision
- MYPS Buy
- GNLX Strong Buy
- Analyst Count
- MYPS 5
- GNLX 4
- Target Price
- MYPS $2.50
- GNLX $17.75
- AVG Volume (30 Days)
- MYPS 239.3K
- GNLX 133.6K
- Earning Date
- MYPS 11-03-2025
- GNLX 11-13-2025
- Dividend Yield
- MYPS N/A
- GNLX N/A
- EPS Growth
- MYPS N/A
- GNLX N/A
- EPS
- MYPS N/A
- GNLX N/A
- Revenue
- MYPS $261,058,000.00
- GNLX N/A
- Revenue This Year
- MYPS N/A
- GNLX N/A
- Revenue Next Year
- MYPS N/A
- GNLX N/A
- P/E Ratio
- MYPS N/A
- GNLX N/A
- Revenue Growth
- MYPS N/A
- GNLX N/A
- 52 Week Low
- MYPS $0.90
- GNLX $1.99
- 52 Week High
- MYPS $2.29
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- MYPS 45.38
- GNLX 71.73
- Support Level
- MYPS $0.93
- GNLX $4.17
- Resistance Level
- MYPS $0.99
- GNLX $5.72
- Average True Range (ATR)
- MYPS 0.04
- GNLX 0.36
- MACD
- MYPS 0.00
- GNLX 0.09
- Stochastic Oscillator
- MYPS 40.45
- GNLX 91.90
About MYPS PLAYSTUDIOS Inc.
PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Company's games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.